Investor Presentaiton

sanofi Drive growth with PCV21 in attractive pediatric market Large pneumococcal vaccine market ~80% €6.8bn (Global, 2022) PCV21: growth driver with strong portfolio fit > Focus on pediatric development > First-in-Class PCV20+ in pediatric population > Synergy with Sanofi pediatric vaccine portfolio > Strong collaboration with SK Bioscience Pediatric Adult / Elderly Source: Pfizer, GSK, Merck 2022 Annual Reports; Sanofi estimates 60 Vaccines Investor Event ~20%

View entire presentation